Literature DB >> 16439592

Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis.

Maki Fukami1, Tomonobu Hasegawa, Reiko Horikawa, Toya Ohashi, Gen Nishimura, Keiko Homma, Tsutomu Ogata.   

Abstract

In this study, we report on three Japanese patients with cytochrome P450 oxidoreductase (POR) deficiency (PORD). Case one was a 46,XY patient who was found to have mildly increased 17alpha-hydroxyprogesterone (17-OHP) by the neonatal mass screening. There was no maternal virilization during pregnancy, and he had no skeletal or genital abnormality. Thus, he was initially diagnosed as having nonclassical 21-hydroxylase deficiency (21-OHD). Cases two and three were 46,XX patients who were identified because of severely virilized external genitalia and maternal virilization during pregnancy. In case two, the neonatal mass screening was normal, and she had no skeletal abnormality except for mild adduction of bilateral third toes. Thus, she was initially diagnosed as having aromatase deficiency. In case three, the neonatal mass screening showed moderately increased 17-OHP, and no skeletal lesion other than rigid second metacarpophalangeal joints was identified in early infancy. Thus, she was initially suspected as having 21-OHD and/or aromatase deficiency. Subsequently, endocrine studies including urine steroid hormone analysis were performed for the assessment of glucocorticoid treatment in case one and for the virilized genitalia in cases two and three, showing adrenal and/or gonadal dysfunction characteristic of PORD. Thus, molecular analysis of POR was carried out, demonstrating homozygosity for R457H in cases one through three. The results imply that clinical features in PORD can be similar to those in 21-OHD or aromatase deficiency, and that comprehensive assessment of the pregnant course, physical examination, and adrenal and gonadal function studies is essential for the precise diagnosis of PORD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439592     DOI: 10.1203/01.pdr.0000195825.31504.28

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

3.  PAH particles perturb prenatal processes and phenotypes: protection from deficits in object discrimination afforded by dampening of brain oxidoreductase following in utero exposure to inhaled benzo(a)pyrene.

Authors:  Zhu Li; Gayathri Chadalapaka; Aramandla Ramesh; Habibeh Khoshbouei; Mark Maguire; Stephen Safe; Raina E Rhoades; Ryan Clark; George Jules; Monique McCallister; Michael Aschner; Darryl B Hood
Journal:  Toxicol Sci       Date:  2011-10-10       Impact factor: 4.849

Review 4.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

5.  Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes.

Authors:  Xingguo Cheng; Jun Gu; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2014-08-21       Impact factor: 3.922

6.  Generation of a mouse model with a reversible hypomorphic cytochrome P450 reductase gene: utility for tissue-specific rescue of the reductase expression, and insights from a resultant mouse model with global suppression of P450 reductase expression in extrahepatic tissues.

Authors:  Yuan Wei; Xin Zhou; Cheng Fang; Lei Li; Kerri Kluetzman; Weizhu Yang; Qing-Yu Zhang; Xinxin Ding
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

7.  Prenatal polycyclic aromatic hydrocarbon exposure leads to behavioral deficits and downregulation of receptor tyrosine kinase, MET.

Authors:  Liu Sheng; Xinxin Ding; Marcus Ferguson; Monique McCallister; Raina Rhoades; Mark Maguire; Aramandla Ramesh; Michael Aschner; Daniel Campbell; Pat Levitt; Darryl B Hood
Journal:  Toxicol Sci       Date:  2010-10-01       Impact factor: 4.849

Review 8.  P450 oxidoreductase deficiency and Antley-Bixler syndrome.

Authors:  Wiebke Arlt
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

9.  The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.

Authors:  Larissa G Gomes; Ningwu Huang; Vishal Agrawal; Berenice B Mendonça; Tania A S S Bachega; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-08       Impact factor: 5.958

10.  Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.

Authors:  Nils Krone; Nicole Reisch; Jan Idkowiak; Vivek Dhir; Hannah E Ivison; Beverly A Hughes; Ian T Rose; Donna M O'Neil; Raymon Vijzelaar; Matthew J Smith; Fiona MacDonald; Trevor R Cole; Nicolai Adolphs; John S Barton; Edward M Blair; Stephen R Braddock; Felicity Collins; Deborah L Cragun; Mehul T Dattani; Ruth Day; Shelley Dougan; Miriam Feist; Michael E Gottschalk; John W Gregory; Michaela Haim; Rachel Harrison; Ann Haskins Olney; Berthold P Hauffa; Peter C Hindmarsh; Robert J Hopkin; Petr E Jira; Marlies Kempers; Michiel N Kerstens; Mohamed M Khalifa; Birgit Köhler; Dominique Maiter; Shelly Nielsen; Stephen M O'Riordan; Christian L Roth; Kate P Shane; Martin Silink; Nike M M L Stikkelbroeck; Elizabeth Sweeney; Maria Szarras-Czapnik; John R Waterson; Lori Williamson; Michaela F Hartmann; Norman F Taylor; Stefan A Wudy; Ewa M Malunowicz; Cedric H L Shackleton; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2011-12-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.